Qhov tshwm sim ntawm GLP-1 receptor agonists yog qhov zoo siab heev - nws tsis yog tsuas yog ntshav qab zib lossis txhaj tshuaj poob phaus xwb, tab sis tib neeg thaum kawg tau pom ib qho "kev siv riam phom" uas tuaj yeem tiv thaiv kev rog thiab nws cov teeb meem hauv lub cev. Kev nkag siab txog kev phom sij ntawm kev rog tsis yog hais txog kev tsim kev ntxhov siab, tab sis hais txog kev hloov pauv ua ntej nws lig dhau lawm.
Ua pa system: suffocation raug mob
Obstructive pw tsaug zog apnea (OSA): Cov rog nyob hauv caj dab thiab caj pas compresses txoj hlab pa, ua rau rov ua pa thaum pw tsaug zog. Qhov tshwm sim ntawm OSA hauv cov neeg rog rog yog siab li 40% -90% (nyob ntawm BMI). Cov txiaj ntsig muaj xws li kev pw tsaug zog nruab hnub, tsis nco qab, thiab muaj kev pheej hmoo ntawm kev tuag sai thaum hmo ntuj.
Kev rog rog hypopnea syndrome: Diaphragmatic compression, txo qhov cua ua haujlwm, ua rau mob hypercapnia thiab hypoxemia.
Mob hawb pob: Kev rog rog ua rau muaj kev pheej hmoo mob hawb pob los ntawm 1.5-2 zaug thiab muaj cov lus teb tsis zoo rau kev kho mob ib txwm muaj.
COPD overlay effect: Kev sib xyaw ua ke ntawm kev rog thiab kev haus luam yeeb ua rau muaj qhov nce ntxiv hauv kev tsis taus thiab kev tuag ntawm cov kab mob ntsws ntev.
Skeletal leeg system: ib qho kev sib tsoo scaffold
Osteoarthritis: Rau txhua qhov hnyav 1 kg, lub hauv caug sib koom ua ke nce 3-5 zaug. Cov tib neeg rog rog muaj 4-5 npaug ntawm kev pheej hmoo siab ntawm lub hauv caug mob caj dab thiab 4.6-fold nce kev pheej hmoo ntawm pob qij txha piv rau cov tib neeg qhov hnyav.
Mob nraub qaum qis: lub lumbar vertebrae dais ntau dhau lub sijhawm ntev, thiab qhov tshwm sim ntawm intervertebral disc herniation thiab txha caj qaum yog nce ntxiv.
Gout: Cov neeg rog rog feem ntau muaj cov ntshav uric acid ntau dua, uas ua rau muaj kev pheej hmoo ntawm kev mob gout los ntawm 2-3 zaug.
Txo kev txav mus los: Cov mob hnyav ua rau tsis muaj peev xwm taug kev ywj pheej, ua rau lub voj voog tsis zoo ntawm "obesity → immobility → rog".
Digestive System: Los ntawm Fatty Liver mus rau Gallbladder Crisis
Cov kab mob uas tsis yog cawv tsis muaj cawv (NAFLD): Kwv yees li 70% -90% ntawm cov neeg rog rog hnyav muaj cov rog rog, ntawm 15% -25% yuav ua rau tsis muaj cawv steatohepatitis (NASH), ntxiv mus rau hauv daim siab fibrosis, cirrhosis, thiab txawm tias mob qog noj ntshav.
Kab mob gallbladder: Kev rog rog ua rau muaj kev pheej hmoo ntawm pob zeb los ntawm 2-3 zaug, thiab kev pheej hmoo ntawm kev phais cholecystectomy kuj nce ntxiv.
Gastroesophageal reflux disease (GERD): Kev mob plab ntau ntxiv ua rau cov kua qaub reflux, uas tuaj yeem ua rau Barrett's esophagus nyob rau lub sijhawm ntev thiab ua rau muaj kev pheej hmoo ntawm esophageal adenocarcinoma.
Wegovy @ ntsiav tshuaj tau ua tiav 21.6% poob phaus hauv cov neeg teb thaum ntxov thiab nce ob npaug ntawm lawv qhov kev txhim kho hauv kev txav mus los.
Thaum Lub Tsib Hlis 13, 2026, Novo Nordisk tau tshaj tawm qhov kev soj ntsuam pab pawg tshiab kawg ntawm Theem 3 OASIS 4 kev sim tshuaj ntawm 2026 European Obesity Conference (ECO2026) muaj nyob rau hauv Istanbul, Qaib ntxhw.
Cov ntaub ntawv qhia tau hais tias piv rau cov placebo, Wegovy @ ntsiav tshuaj (25mg semaglutide ntsiav tshuaj) muaj txiaj ntsig zoo rau cov neeg mob rog rog.
Cov txiaj ntsig kev tshawb fawb tam sim no qhia tau tias ze li ntawm ib - thib peb (28.8%) noj Wegov ® Cov neeg laus uas tau teb rau cov ntsiav tshuaj thaum ntxov ntawm kev kho mob (piv txwv li qhov hnyav poob ntawm 210% ntawm lub lim tiam 16) tau poob qhov nruab nrab ntawm 13.2% ntawm lub lim tiam 16. Qhov nruab nrab qhov hnyav ntawm cov neeg teb thaum ntxov no tau nce ntxiv mus rau 4 lub lim tiam ntawm 6%. Nyob rau tib lub sijhawm, cov kev kawm uas tsis ua raws li cov txheej txheem rau "cov lus teb thaum ntxov" tseem ua tiav qhov hnyav ntawm 11.5% thaum kawg ntawm kev sim.
Qhov no qhia tau hais tias los ntawm qhov kawg ntawm qhov kev sim, ob pawg tau ua tiav kev kho mob hnyav hnyav. Ntxiv rau qhov poob phaus tseem ceeb, lwm qhov kev tshuaj xyuas ntawm OASIS 4 qhov kev sim luam tawm hauv ECO2026 tau pom tias ze li ntawm 80% ntawm cov neeg mob uas muaj lub cev tsis zoo ntawm cov neeg noj Wegovy @ ntsiav tshuaj tau ua tiav kev kho mob tseem ceeb hauv cov qhab nia ua haujlwm (77.3%, piv rau 42.9% hauv pawg placebo).
Cov qhab nia ua haujlwm no yog siv los ntsuas ntau yam ntawm lub cev muaj peev xwm ua si, suav nrog ntau yam ntawm kev txav thiab kev ua siab ntev. Nyob rau tib lub sijhawm, qhov poob phaus ua tiav los ntawm cov pejxeem no yog piv rau tag nrho Weqovy ® Cov pejxeem ntawm cov neeg siv ntsiav tshuaj yog qhov zoo sib xws.
Cov pov thawj tshiab ntawm qhov ntev - lub sij hawm yuag hnyav nqa los ntawm Eli Lilly orforglipron thiab qis - koob tshuaj tepaglutide
Thaum Lub Tsib Hlis 13, 2026, Eli Lilly tau tshaj tawm cov ntsiab lus ntxaws ntawm ob qhov kev tshawb fawb kho mob lig, SURMUNT-MAINTAIN thiab ATTAIN-MAINTAIN.
Kev tshawb fawb tau pom tias cov neeg rog rog tuaj yeem ua tiav ntev - lub sij hawm poob phaus tom qab tau txais siab - koob tshuaj titrated ntawm kev kho mob enteropancreatin, txawm tias hloov mus rau orforglipron lossis txo qis cov koob tshuaj tilboptin. Cov txiaj ntsig kev tshawb fawb ntawm SURMUNT-MAINTAIN thiab ATTAIN-MAINTAIN tau nthuav tawm ntawm 33rd European Conference on Obesity (ECO) thiab luam tawm nyob rau hauv The Lancet and Nature Medicine, feem.
Hauv SURMOUNT-TAIN txoj kev tshawb fawb, ob qho tib si qhov siab tshaj plaws ntawm koob tshuaj (MTD) thiab 5mg koob tshuaj tiltrotide tau mus txog qhov kawg ntawm thawj qhov kawg thiab tag nrho cov ntsiab lus tseem ceeb thib ob, qhia tias kev tswj hwm MTD ntawm tiltrotide thiab txo cov koob tshuaj rau 5mg yog ob qho tib si hauv kev tswj qhov hnyav tom qab 60 lub lis piam ntawm kev kho mob tiltide. Lub ntsiab lus kawg ntawm txoj kev tshawb fawb yog los soj ntsuam tias nyob rau lub lim tiam 112, txuas ntxiv tau txais kev kho mob tiltrotide - txawm tias txo cov koob tshuaj mus rau 5mg lossis tswj qhov siab tshaj plaws ntawm koob tshuaj - ua rau muaj feem pua ntawm qhov hnyav dua piv rau cov hauv paus piv rau cov placebo.
Cov txiaj ntsig tau pom tias nyob rau lub lim tiam 112, cov neeg mob uas txuas ntxiv siv Terpotide MTD tuaj yeem tswj hwm lawv qhov hnyav dhau los ntawm qhov nruab nrab, thaum cov neeg uas txo cov koob tshuaj rau 5mg tsuas yog rov qab tau qhov nruab nrab ntawm 5.6kg. Terpotide yog kev txhaj tshuaj txhua lub limtiam ntawm cov piam thaj nyob ntawm insulinotropic polypeptide (GIP) / glucagon zoo li peptide-1 (GLP-1) receptor agonist, uas yog ib leeg-molecule peptide chav kawm ntawm cov tshuaj, uas tuaj yeem khi rau thiab qhib tib neeg lub cev lub plab hnyuv glucagon receptors, uas yog GIP-1 receptors. Nws yog tsim nyog sau cia tias ob qho tib si receptors tau qhia nyob rau hauv cov cheeb tsam tseem ceeb ntawm lub hlwb uas tsis zoo tswj kev qab los noj mov, thiab Terpotide tau pom los tswj kev qab los noj mov mechanisms. Txo lub zog kom tsawg hauv tib neeg lub cev.
Tam sim no, kev tshawb fawb ntawm daim ntawv thov ntawm tilpotide hauv cov neeg mob uas muaj kab mob raum ntev (CKD) thiab nws cov koom haum nrog comorbidities thiab mortality (MMO) hauv cov neeg mob rog yog tseem txuas ntxiv mus.